Core Viewpoint - Berman Tabacco is investigating potential stockholder claims against SelectQuote, Inc. regarding allegations of illegal payments received from health insurance providers [1][2]. Investigation Details - Allegations against SelectQuote were unsealed in May 2025, involving claims that the company received illegal payments totaling over 80 million dollars from Humana and Aetna between 2016 and 2021 [2]. - The complaint suggests that SelectQuote was incentivized to direct customers towards Medicare offerings from these insurance carriers [2]. - It is alleged that senior officers of SelectQuote were personally involved in this scheme, leading to a significant decline of approximately 20% in SelectQuote's shares following the Department of Justice's complaint [2]. Board and Fiduciary Duties - Berman Tabacco is examining whether SelectQuote's board of directors played a role in the alleged scheme and if there were breaches of fiduciary duties by its officers and/or directors [3].

Core Viewpoint - Berman Tabacco is investigating potential stockholder claims against Humana, Inc. regarding allegations of illegal kickbacks paid to insurance brokers [1][2] Group 1: Allegations and Investigation - Allegations against Humana involve the payment of illegal kickbacks totaling possibly up to $250 million to insurance brokers, including Select Quote, to direct customers towards Humana's Medicare offerings [2] - The investigation was prompted by a whistleblower and has been supported by the U.S. Attorney's Office for the District of Massachusetts [2] - The complaint suggests that senior officers of Humana were personally involved in the alleged scheme [2] Group 2: Impact on Stock Performance - Following the filing of the complaint, shares of Humana experienced a decline of approximately 3% [2] Group 3: Board and Fiduciary Duties - Berman Tabacco is examining whether Humana's board of directors had a role in the alleged kickback scheme and if there were breaches of fiduciary duties by its officers and/or directors [3]